Highlights

The vaccine will be affordable & accessible
Cervical cancer in India ranks as the second-most frequent cancer among women
Phase three results showed a robust immune response in 100% of the vaccine recipients

Latest news

Apple iPhone Duo Price In India: What Do You Get For ₹2,99,900?

iPhone Duo Costs ₹2,99,900 In India. Here’s What It Costs In Other Countries

iPhone 18 Pro vs iPhone 17 Pro: What Does Apple Actually Give You For ₹1.65 Lakh?

Google Pixel 11 Pro XL Review: Google Knows Exactly What It’s Good At

Logitech Launches MX Keypad in India, Brings Physical Controls to AI Coding Workflows

Smartphone Habits Are Reshaping What Indian Consumers Expect From Laptops and AI PCs

India Is Buying Fewer Smartphones, But Spending More. POCO Says ‘Value’ Has Fundamentally Changed

POCO X8, X8 Power Launched in India With Up to 10,000mAh Battery, 100W Charging

Good news! India to launch cervical cancer vaccine by year-end

Name: Good news! India to launch cervical cancer vaccine by year-end
Uploaded: 2022-07-20T11:12:44.000+05:30
Duration: T00M58S
Channel: Editorji News Desk
Description: Cancer Vaccine: The Serum Institute of India (SII) is all set to launch its indigenously-developed cervical cancer vaccine by the end of this year.

Cervical Cancer Vaccine : The Serum Institute of India (SII) is all set to launch its indigenously-developed cervical cancer vaccine by the end of this year.

Updated: Sep 02, 2022 10:53

Editorji News Desk

Join our WhatsApp Channel

Good news! India to launch cervical cancer vaccine by year-end

Cancer Vaccine: After the Drugs Controller General of India's (DCGI) approval, the Serum Institute of India (SII) is all set to launch its indigenously-developed cervical cancer vaccine later this year.

According to SII, the Quadrivalent Human Papillomavirus vaccine (qHPV) to treat cervical cancer in women will be affordable and accessible.

Cervical cancer in India ranks as the second-most frequent cancer among women between 15 and 44 years of age. The vaccine is based on VLP (virus-like particles), similar to the Hepatitis B vaccine and protects by generating antibodies against the HPV virus L1 protein.

The trials for the vaccine started in 2019 and thousands of participants in the age group of 9‐26 years were part of the trials across India. Phase three results showed a robust immune response in 100 per cent of the vaccine recipients with good safety records.

Also watch: Researchers develop a new single-shot vaccine to cure AIDS